EE84 Cost-Effectiveness of Pembrolizumab Plus Nab-paclitaxel in Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) Whose Tumors Expressed Pd-L1 (CPS ≥10) in Colombia
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.388
https://www.valueinhealthjournal.com/article/S1098-3015(23)00488-6/fulltext
Title :
EE84 Cost-Effectiveness of Pembrolizumab Plus Nab-paclitaxel in Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) Whose Tumors Expressed Pd-L1 (CPS ≥10) in Colombia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00488-6&doi=10.1016/j.jval.2023.03.388
First page :
Section Title :
Open access? :
No
Section Order :
11771